Skuja Elina, Kalniete Dagnija, Nakazawa-Miklasevica Miki, Daneberga Zanda, Abolins Arnis, Purkalne Gunta, Miklasevics Edvins
Clinic of Oncology, Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia; Institute of Oncology, Riga Stradins University, LV-1007 Riga, Latvia.
Institute of Oncology, Riga Stradins University, LV-1007 Riga, Latvia.
Mol Clin Oncol. 2017 Feb;6(2):182-186. doi: 10.3892/mco.2017.1123. Epub 2017 Jan 2.
Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromothripsis and total breakpoint count (breakpoint instability index) on progression-free survival (PFS). A total of 19 patients with metastatic CRC (mCRC) receiving FOLFOX first-line palliative chemotherapy between August, 2011 and October, 2012 were selected for this study. The results indicated that the highest breakpoint count was observed in chromosomes 1, 2 and 6. Chromothripsis was detected in 52.6% of the study patients. Furthermore, chromothripsis was associated with an increased median PFS (mPFS; 14 vs. 8 months, respectively; P=0.03), but an association with overall survival was not identified. The present study demonstrated that chromothripsis affected CRC patient survival, suggesting a role for this event as a prognostic and predictive marker in mCRC treatment.
原发性肿瘤的转移扩散是结直肠癌（CRC）患者死亡的主要原因。多个染色体断裂和染色体碎裂（一种在单个灾难性事件中发生多个染色体片段化的现象）与癌症的发生、进展及转移的发展相关。本研究的目的是评估染色体碎裂和总断点计数（断点不稳定指数）对无进展生存期（PFS）的影响。本研究选取了2011年8月至2012年10月期间共19例接受FOLFOX一线姑息化疗的转移性结直肠癌（mCRC）患者。结果表明，在1号、2号和6号染色体中观察到最高的断点计数。在52.6%的研究患者中检测到染色体碎裂。此外，染色体碎裂与中位无进展生存期（mPFS）增加相关（分别为14个月和8个月；P=0.03），但未发现与总生存期相关。本研究表明，染色体碎裂影响CRC患者的生存，提示该事件在mCRC治疗中作为预后和预测标志物的作用。
